Hematologie, kliniek en laboratoriumdiagnostiek, ISBN: 978 94 91764 74 5

Eerste herziene druk, © 2026, Syntax Media, Amersfoort

www.syntaxmedia.nl

Literatuur

Hoofdstuk 1

James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, Haberichter S, Jacobs-Pratt V, Konkle B, McLintock C, McRae S, R Montgomery R, O'Donnell JS, Scappe N, Sidonio R, Flood VH, Husainat N, Kalot MA, Mustafa RA*. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv.* 2021 Jan 12;5(1):280-300.

Boender J, Eikenboom J, van der Bom JG, et al. *Clinically relevant differences between assays for von Willebrand factor activity.* J Thromb Haemost 2018;16(12):2413-24.

Vangenechten I, Mayger K, Smejkal P, et al. *A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.* J Thromb Haemost 2018;16(7):1268-77*.*

James PD, Connell NT, Armeer B et al*. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv* 2021;5(1):280-300.

Kalot MA, Husainat N, Abughanimeh O et al. *Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: A systematic review and meta-analysis which informed the VWD diagnosis guidelines. Blood Adv* 2022;6(12):3735-45.

Keeney S, Bowen D, Cummings A, et al. *The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network.* Hameophilia 2008;14(5):1099-111.

Swystun LL, James PD. *Genetic diagnosis in hemophilia and von Willebrand disease. Blood Rev* 2017;31(1):47-56.

James PD, Connell NT, Armeer B et al. *ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv* 2021;5(1):280-300.

Kalot MA, Husainat N, El Alayli A et al. *Von Willebrand factor levels in the diagnosis of Von Willebrand Disease: A systematic review and meta-analysis. Blood Adv* 2022;6(1):62-71.

Leebeek FWG, Eikenboom JCJ. *Von Willebrand's disease.* N Engl J Med. 2016;375:2067-80

Sharma R, Flood VH*. Advances in the diagnosis and treatment of Von Willebrand disease. Blood* 2017;130(22):2386-91.

James P, Leebeek F, Casari C, Lillicrap D*. Diagnosis and treatment of von Willebrand disease in 2024 and beyond. Haemophilia.* 2024 Apr;30 Suppl 3:103-111. doi: 10.1111/hae.14970. Epub 2024 Mar 13. PMID: 38481079.

Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A*.1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases.* Lancet 1977;1(8017):869-72.

Castaman G, Lethagen S, Federici AB, et al. *Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.* Blood 2008;111(7):3531-9.

Federici AB, Mannucci PM, Castaman G, et al. *Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.* Blood 2009;113(3):526-34.

Mannucci PM, Duga S, Peyvandi F. *Recessively inherited coagulation disorders.* Blood 2004;104(5):1243-52.

Mariani G, Herrmann FH, Dolce A, et al. *Clinical phenotypes and factor VII genotype in congenital factor VII deficiency.* Thromb Haemost 2005;93(3):481-7.

Mumford AD, Ackroyd S, Alikhan R, et al. *Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology.* Br J Haematol 2014;167(3):304-26.

Palla R, Peyvandi F, Shapiro AD. *Rare bleeding disorders: diagnosis and treatment.* Blood 2015;125(13):2052-61.
Peyvandi F, Palla R, Menegatti M, et al. *Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.* J Thromb Haemost 2012;10(4):615-21.